Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002038897 | SCV002313668 | likely pathogenic | not provided | 2023-03-13 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1523468). This variant has not been reported in the literature in individuals affected with TRMU-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change affects a splice site in intron 3 of the TRMU gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TRMU are known to be pathogenic (PMID: 19732863, 23625533). |
| Fulgent Genetics, |
RCV002492399 | SCV002794773 | likely pathogenic | Aminoglycoside-induced deafness; Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins | 2022-03-09 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV003475300 | SCV004204384 | likely pathogenic | Aminoglycoside-induced deafness | 2023-04-17 | criteria provided, single submitter | clinical testing |